RodenMM, ZaoutisTE, BuchananWL, KnudsenTA, SarkisovaTA, SchaufeleRL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis, 2005; 41(5):634-653.
3.
SpellbergB, KontoyiannisDP, FredricksD, MorrisMI, PerfectJR, Chin-HongPV, et al. Risk factors for mortality in patients with mucormycosis. Med Mycol, 2012; 50(6):611-618.
4.
LeeFY, MossadSB, AdalKA. Pulmonary mucormycosis: the last 30 years. Arch Intern Med, 1999; 159(12):1301-1309.
WahidiMM, RochaAT, HollingsworthJW, GovertJA, Feller-KopmanD, ErnstA. Contraindications and safety of transbronchial lung biopsy via flexible bronchoscopy. A survey of pulmonologists and review of the literature. Respiration, 2005; 72(3):285-295.
7.
SpellbergB, IbrahimAS. Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep, 2010; 12(6):423-429.
8.
SaegemanV, MaertensJ, EctorsN, MeerssemanW, LagrouK. Epidemiology of mucormycosis: review of 18 cases in a tertiary care hospital. Med Mycol, 2010; 48(2):245-254.
9.
ChamillosG, LewisRE, KontoyiannisDP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis, 2008; 47(4):503-509.
SpellbergB, WalshTJ, KontoyiannisDP, EdwardsJJr, IbrahimAS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis, 2009; 48(5):1743-5112.
12.
GrigullL, BeilkenA, SchmidH, KirschnerP, SykoraKW, LinderkampC, et al. Secondary prophylaxis of invasive fungal infections with combination antifungal therapy and G-CSF-mobilized granulocyte transfusions in three children with hematological malignancies. Support Care Cancer, 2006; 14(7):783-786.
13.
JohnB V, ChamilosG, KontoyiannisDP. Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin Microbiol Infect, 2005; 11(7):515-517.
